CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- $300,000
- Closes
- Nov 5, 2028 (in 830 days)
Classification and identifiers
- Solicitation number
- PAR-27-075
- Assistance listing (CFDA)
- 93.855
Amount
$300,000
Who can apply
Private colleges and universities can apply here. Check the eligibility details below to see if your organization fits.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this opportunity
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit basic research applications to investigate the pathological mechanisms of skin injuries caused by toxic Chemicals of Concern (CoC) identified as public health threats by the United States Government. This NOFO supports the goal of the trans-NIH Chemical Countermeasures Research Program (CCRP) and is intended to spur the discovery and early development of broad-spectrum medical countermeasures (MCMs) to advance the nation's medical and public health preparedness for, response to, and recovery from high consequence chemical disasters and emergencies.
Related opportunities
- Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)National Institutes of HealthCloses Jan 2028
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $300K
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $150K